Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

In this episode, I talked with Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, a Copenhagen-based biotech developing GIPR antagonists in the obesity space.

Richard’s career began in the NHS, where he spent five years practicing acute medicine and intensive care—until the moment he realized he couldn’t picture himself doing the same thing for the next 30 years. That realization sparked a pivot that many physicians quietly wrestle with: leaving behind the security of the ward for the uncertainty of industry.

Richard also shares what it was like to walk away from a stable VP role at Bayer during a restructuring, take an intentional career break, and use those months to reflect on what really mattered before joining Antag Therapeutics. We talk about the shift from big pharma to biotech, what he learned from leading through severe stakeholder misalignment, and why authentic communication matters more than management theory when things get messy.

And yes—there’s a light-hearted detour into Berlin life, bad currywurst, and how to tell when it’s time to make serious changes in your team.

Here’s What You’re In For

  1. What makes Antag Therapeutics’ culture unique
  2. The hardest leadership call: deciding when the problem is you vs them
  3. The recruitment ghosting story that every hiring manager should hear


Timestamps

02:08 – Leaving the NHS: deciding what he could be “happily bored with”

04:00 – Landing his first pharma job at Bayer in drug safety

09:33 – Overview of Antag Therapeutics and GIPR vs GLP-1

13:20 – Leaving Bayer and taking a sabbatical to reset

17:08 – What it’s like to work at Antag Therapeutics—and what he looks for in candidates

18:46 – The toughest chapter: extreme stakeholder misalignment in dermatology

25:16 – Leadership lessons: firing, feedback, and the “benefit of the doubt”

29:00 – Why managers struggle to act fast—and how structure slows decisions

31:48 – Richard’s worst recruitment experience: being ghosted by agencies


About Richard

Richard Nkulikiyinka, is the Chief Medical Officer of Antag Therapeutics, a biotech developing GIPR antagonists within the Obesity space. A UK-trained physician, he spent five years practicing in acute medicine and intensive care within the NHS - this is also where he developed his dry sense of humour - and now he transitioned into the biopharmaceutical industry, where he has built over 17 years of experience.

Prior to joining Antag, Richard served as Vice President in Clinical Development at Bayer Pharma, where he played a central role in advancing four drugs to approval. He is now ein Berliner - where we often meet for clubbing and currywurst.

Connect with Richard:

  1. LinkedIn: https://www.linkedin.com/in/richard-nkulikiyinka-66336014/
  2. Website: https://antagtx.com/


About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment, I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with me:

  1. LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/
  2. Website: https://www.discera-search.com/


Opinions and comments expressed by the guest do not represent the company and are fully their own.

Jaksot(67)

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Maalis 42min

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

In this episode, I talked with Volker Wacheck, SVP & Head of Clinical Development at Taiho Oncology, where he shared how a PI role in Vienna led him into industry, and why the hardest part wasn’t leav...

9 Maalis 29min

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

In this episode, I talked with Dr. Dena Grayson, a physician–scientist with over two decades in biotech drug development. At the time of this recording, she was SVP and Head of Clinical Development at...

24 Helmi 31min

Prof. Dr. med. Markus Kosch, Head of Oncology Europe & Canada at Daiichi Sankyo on Perseverance, Patient-Centricity Beyond Slogans, and Leadership within Oncology

Prof. Dr. med. Markus Kosch, Head of Oncology Europe & Canada at Daiichi Sankyo on Perseverance, Patient-Centricity Beyond Slogans, and Leadership within Oncology

In this episode, I talked with Prof. Dr. med. Markus Kosch, Head of Oncology Europe and Canada at Daiichi Sankyo Europe, about what it really means to lead with empathy, perseverance, and purpose in t...

19 Tammi 35min

Myriam Cherif, Founder of Kalyx Medical, on The Future of MSLs, Adapting to AI, and Why Curiosity Keeps You Moving Forward

Myriam Cherif, Founder of Kalyx Medical, on The Future of MSLs, Adapting to AI, and Why Curiosity Keeps You Moving Forward

In this episode, I talked with Myriam Cherif, former Regional Medical Lead for Oncology & Emerging Markets at GSK and founder of Kalyx Medical—a consultancy focused on Medical Affairs strategy, mentor...

5 Tammi 33min

Sven Van den Berghe, CEO of Pantera on Overpromises in Isotope Marketing, Why Culture is the Company, and Discussions in RLT Development

Sven Van den Berghe, CEO of Pantera on Overpromises in Isotope Marketing, Why Culture is the Company, and Discussions in RLT Development

In this episode, I talked with Sven Van den Berghe, CEO of Pantera, about his 25+ years in nuclear physics, from his early days at the Belgian Nuclear Research Center to stepping into the high-stakes ...

17 Marras 202527min

Catello Somma, Partner at Seroba on Working in VC, Non-Linear Biotech Careers, and advice for those seeking VC careers

Catello Somma, Partner at Seroba on Working in VC, Non-Linear Biotech Careers, and advice for those seeking VC careers

In this episode, I talked with Catello Somma, Partner at Seroba, to learn about his nonlinear journey from academia and biopharma into venture capital—and the realities behind building funds, backing ...

10 Marras 202521min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
mimmit-sijoittaa
rss-rahapodi
psykopodiaa-podcast
hyva-paha-johtaminen
rss-rahamania
inderespodi
rss-lahtijat
rss-oivalluksia-rahasta-elamasta
ostan-asuntoja-podcast
rahapuhetta
oppimisen-psykologia
rss-bisnesta-bebeja
rss-sisalto-kuntoon
herrasmieshakkerit
leadcast
lakicast
rss-startup-ministerio
rss-rikasta-elamaa
rss-inderes